Erythropoietin: Physiology and pharmacology update

Experimental Biology and Medicine

Volumn 228, Issue 1, 2003, Pages 1-14

  Fisher, James W ^a  

^a NONE

Author keywords

Adenosine; Anemia; Darbepoetin; Doping; Erythropoiesis; Erythropoietin; Hypoxia; Hypoxia inducible factor; Oxygen; Receptor

Indexed keywords

ERYTHROPOIETIN; GLYCOPROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

AMINO ACID SEQUENCE; ANEMIA; CELL PROLIFERATION; COLONY FORMING UNIT E; DRUG EFFECT; ENHANCER REGION; ERYTHROID CELL; ERYTHROPOIESIS; GENE EXPRESSION REGULATION; HEMATOCRIT; HYPOXIA; PHYSIOLOGY; PLASMA HALF LIFE; RECEPTOR BINDING; RETICULOCYTOSIS; SHORT SURVEY; SIGNAL TRANSDUCTION; SURGICAL PATIENT;

JANUS;

EID: 0037227316     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020322800101     Document Type: Short Survey

References (196)

1. Fisher JW. Eyrthropoietin: physiologic and pharmacologic aspects. Proc Soc Exp Biol Med 216:358-369, 1997.
2. Carnot P, DeFlandre C. Sur l'activite hemopoietique de serum au cours de la regeneration du sang. C R Acad Sci (Paris) 143:384-386, 1906.
3. Gibelli C. Uber den wert des serums anamisch gemachten tiere bei der regeneration des blutes. Arch Exp Pathol Pharmacol 65:284-302, 1911.
4. Sandor G. Uber die blutbidende wirkung des serums von tieren, die in verdunnter luft gehalten wuren. Z Gesante Exp Med 82:633-646, 1932.
5. Hjort E. Reticulocyte increase after injection of anemic serum. Mag F Laegividensk 97:270-277, 1936.
6. Krumdieck N. Erythropoietic substance in the serum of anemic animals. Proc Soc Exp Biol Med 54:14-17, 1943.
7. Erslev AJ. Humoral regulation of red cell production. Blood 8:349-357, 1953.
8. Reissmann KR. Studies on the mechanism of erythropoietin stimulation in parabiotic rats during hypoxia. Blood 5:347-380, 1950.
9. Jacobson LO, Goldwasser E, Fried W, Plzak L. Role of the kidney in erythropoiesis. Nature 179:633, 1957.
10. Fisher JW, Birdwell BJ. Erythropoietin production by the in situ perfused kidney. Acta Haematol 26:224-232, 1961.
11. Kuratowska Z, Lewartowski B, Michalski E. Studies on the production of erythropoietin by isolated perfused organs. Blood 18:527-534, 1961.
12. Erslev AJ. In vitro production of erythropoietin by kidneys perfused with a serum free solution. Blood 44:77-85, 1974.
13. Koury ST, Bondurant MS, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 71:524-537, 1988.
14. Fisher JW, Koury S, Ducey T, Mendel S. Erythropoietin (Epo) production by interstitial cells of hypoxic monkey kindeys. Br J Haematol 95:27-32, 1996.
15. Zanjani ED, Poster J, Burlington H, Mann LI, Wasserman LR. Liver as the primary site of erythropoietin production in the fetus. J Lab Clin Med 89:640-644, 1977.
16. Koury ST, Bondurant MC, Koury MJ, Semenza GL. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 77:2497-2503, 1991.
17. Miyake T, Kung CKH, Goldwasser E. Purification of human erythropoietin. J Biol Chem 252:5558-5564, 1977.
18. Lin FK, Suggs S, Lin CH, Browne JK, Smailing R, Egric JC, Chen KK, Fox GM, Martin F, Wasser Z. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 92:7850-7884, 1985.
19. Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, Seehra A, Jones SS, Hewick R, Fritsch EF, Kawakita M, Shimiza T, Miyoke T. Isolation and characterization of genomic cDNA clones of human erythropoietin. Nature 313:806-810, 1985.
20. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84(Suppl 1):3-10, 2001.
21. MacDougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 20:375-381, 2000.
22. Lacombe C, DaSilva JL, Bruneval P, Fournier JG, Wendling F, Casadevall N, Camilleri JP, Bariety J, Varet B, Tambourin P. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 81:620-623, 1988.
23. Semenza GL, Koury ST, Nejfelt MK, Gearhart JD, Antonarakis SE. Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice. Proc Natl Acad Sci U S A 88: 8725-8729, 1991.
24. Darby IA, Evans BA, Fu P, Lim GM, Moritz KM, Wintour EM. Erythropoietin gene expression in fetal and adult sheep kidney. Br J Haematol 89:266-270, 1995.
25. Maxwell AP, Lappin TR, Johnston J, Bridges CF, McGeown MG. Erythropoietin production in kidney tubular cells. Br J Haematol 74: 535-539, 1990.
26. Loya F, Yang Y, Lin H, Goldwasser E, Albitar M. Transgenic mice carrying the erythropoietin gene promoter linked to lacZ express the reporter in proximal convoluted tubule cells after hypoxia. Blood 84: 1831-1836, 1994.
27. Mujais SK, Bery N, Pullman TN, Goldwasser E. Erythropoietin is produced by tubular cells of the rat kidney. Cell Biochem. Biophysics 30:153-166, 1999.
28. Smith DH, Maples PB, Beru N, Goldwasser E. Identification of erythropoietin producing cells in mammalian kidneys by in situ hybridization. Blood 68:170A, 1986.
29. Rich IN, Noe GI, Vogt CA, L'emke C. Erythropoietin is produced in the tubules of the renal cortex. Blood 76 (Suppl 1):639A, 1990.
30. Da Silva JL, Schwartzman ML, Goodman A, Levere RD, Abraham NG. Localization of erythropoietin mRNA in the rat kidney by polymerase chain reaction. J Cell Biochem 54:239-246, 1994.
31. Gregory CJ, Eaves AC. Human marrow cells capable of erythropoietic differentiation in vitro: definition of three erythroid colony responses. Blood 49:855-864, 1974.
32. Gregory CJ, Eaves AC. Three stages of erythropoietic progenitor cell differentiation distinguished by a number of physical and biologic properties. Blood 51:527-537, 1978.
33. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83:59-67, 1995.
34. Lin CS, Lim SK, D'Agati V, Costantini F. Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genus Dev 10:154-164, 1996.
35. Wu H, Klingmuller U, Besmer P, Lodish HF. Interaction of the erythropoietin and stem-cell-factor receptors. Nature 377:242-246, 1995.
36. Jacobs-Helber SM, Penta K, Sun Z, Lawson A, Sawyer ST. Distinct signaling from stem cell factor and erythropoietin in HCD57 cells. J Biol Chem 272:6850-6853, 1997.
37. Dessypris EN, Gleaton JH, Armstrong OL. Effect of human recombinant erythropoietin on human marrow megakaryocyte colony formation in vitro. Br J Haematol 65:265-269, 1987.
38. D'Andrea AD, Zon LI. Erythropoietin receptor: colon subunit structure and activation. J Clin Invest 86:681-687, 1990.
39. Sawada K, Krantz SB, Dai C-H, Koury ST, Horn ST, Glick AD, Civin CI. Purification of human blood burst-forming units-erythroid and demonstration of the evolution of erythropoietin receptor. J Cell Physiol 142:219-230, 1990.
40. Wickrema A, Krantz SB, Winkelmann JC, Bondurant MC. Differentiation and erythropoietin receptor gene expression in human erythroid progenitor cells. Blood 80:1940-1949, 1992.
41. Sawyer ST, Koury MJ. Erythropoietin requirement during terminal erythroid differentiation: the role of surface receptors for erythropoietin (Abs). J Cell Biol 105:1077, 1987.
42. D'Andrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythropoietin receptor. Cell 57:277-285, 1989.
43. Livuah O, Stura EA, Middleton SA, Johnson DC, Jokiffe CK, Wilson TA. Crystallographic evidence for performed divers of erythropoietin receptor before ligand activation. Science 283:987-990, 1999.
44. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science 283:990-993, 1999.
45. Philo JS, Aoki KH, Arkaws T, Nahri LO, Wen J. Dimerization of the extracellular domain of the erythropoietin (Epo) receptor by Epo: one high-affinity and one low-affinity interaction. Biochemistry 35:1681-1691, 1996.
46. Kubatzky KK, Ruan W, Gurezka R, Cohen J, Kettelr R, Watowich, Neumann D, Langosch D, Klingmuller U. Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptor. Curr Biol 11:110-115, 2001.
47. Constantinescu JN, Keren T, Socolovsky M, Nam H, Henis YI, Lodish HF. Ligand-independent oligomerizatin of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci U S A 98:4379-4384, 2001.
48. Mayeux P, Lacombe C, Casadevall N, Chretien S, Dusanter I, Gisselbrecht S. Structure of the murine erythropoietin receptor complex. Characterization of the erythropoietin cross-linked proteins. J Biol Chem 266:23380-23385, 1991.
49. Qiu H, Belanger A, Yoon HW, Bunn HF. Homodimerization restores biological activity to an inactive erythropoietin mutant. J Biol Chem 273:11173-11176, 1998.
50. Witthuhn B, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following Epo stimulation. Cell 74:227-236, 1996.
51. Hilton CJ, Berridge MV. Conserved region of the cytoplasmic domain is not essential for erythropoietin-dependent growth. Growth Factors 121:263-276, 1995.
52. Miura O, D'Andrea A, Kabat D, Ihle JN. Induction of tyrosine phosphorylation by the erythropoietin receptor correlates with mitogenesis. Mol Cell Biol 11:4895-4902, 1991.
53. Yoshimura A, Lodish HF. In vitro phosphorylation of the erythropoietin receptor and an associated protein, pp130. Mol Cell Biol 12: 706-715, 1992.
54. Constantinescu SN, Huang LJ, Nam H, Lodish HF. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Mol Cell 7:377-385, 2001.
55. Zang H, Sato K, Nakajuma H, McKay C, Ney PA, Ihle JN. The distal region and receptor tyrosines of the EPO receptor are non-essential for in vivo erythropoiesis. EMBO J 20:3156-3166, 2001.
56. Von Lindern M, Parren-Von Amehvort M, Von Dijk T, Deiner E, Von Den Akker E, Von Erst-de Vries S, Williams P, Beng H, Lowenberg B. Protein kinase c-α controls erythropoietin receptor signaling. J Biol Chem 275:34719-34727, 2000.
57. Koury MJ, Sawyer ST, Brandt SJ. New insights into erythropoiesis. Curr Opin Hematol 9:93-100, 2002.
58. Carrol MP, Spivak JL, McMahon M, Weich N, Rapp UR, May WS. Erythropoietin induces Raf-1 activation and Raf-1 is required for erythropoietin-mediated proliferation. J Biol Chem 266:14964-14969, 1991.
59. Gobert S, Duprez V, Lacombe C, Gisselbrecht S, Mayeux P. Erythropoietin activates three forms of MAP kinase in UT7 erythroleukemia cells. Eur J Biochem 234:75-83, 1995.
60. Miura Y, Muira O, Ihle JN, Aoki N. Activation of the mitogen activated protein kinase pathway by the erythropoietin receptor. J Biol Chem 269:29962-29969, 1994.
61. Damen JE, Mui ALF, Puil L, Pawson T, Krystal G. Phosphatidylinositol 3-kinase associates, via its Src homology 2 domains, with the activated erythropoietin receptor. Blood 81:3204-3210, 1996.
62. Damen J, Cutler RL, Jiao H, Yi T, Krystal G. Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the p85 subunit of phosphatidylinositol (PI) 3-kinase and for EpR-associated PI 3-kinase activity. J Biol Chem 270:23402-23406, 1995.
63. Verdier F, Chretien S, Billat C, Gisselbrecht S, LaCombe C, Mayeux P. Erythropoietin induces the tyrosine phosphorylation of insulin receptor substrate-2: an alternate pathway for erythropoietin-induced phosphatidylinositol 3-kinase activation. J Biol Chem 272:26173-26178, 1997.
64. Pallard C, Fabrice G, Martine C, Groner B, Gisselbrecht S, Dusanter-Fourt I. Interleukin-3, erythropoietin, and prolactin activate a STAT5 line factor in lymphoid cells. J Biol Chem 270:15942-15945, 1995.
65. Wakao H, Harada N, Kitamura T, Mui ALF, Miyajima A. Interleukin 2 and erythropoietin activate STAT5/MGF via distinct pathways. EMBO J 14:2527-2535, 1995.
66. Penta K, Sawyer ST. Erythropoietin induces the tyrosine phosphorylation nuclear translocation and DNA binding of STAT1 and STAT5 in erythroid cells. J Biol Chem 270:31282-31287, 1995.
67. Watowich SS, Mikami A, Busche RA, Xie X, Pharr PN, Hongmore GD, Manduit P, Sabbah M, Druker B, Vainchenker W, Fisher S, Lacombe C, Gisselbreccht S. Erythropoietin receptors that signal through Stat5 or Stat3 support fetal liver and adult erythropoiesis: lack of specificity of STAT signals during Red Blood Cell Development. J Interferon Cytokine Res 20:1065-1070, 2000.
68. Ihle JN. Cytokine receptor signaling. Nature 377:591-594, 1995.
69. Damen JE, Wakao H, Miyajima A, Krosl J, Humphries RK, Cutler RL, Krystal G. Tyrosine 343 in the erythropoietin-receptor positively regulates erythropoietin-induced cell proliferation and STAT5 activation. EMBO J 14:5557-5568, 1995.
70. Chrétien S, Varlet P, Verdier F, Gobert S, Cartron JP, Gisseelbrecht S, Mayeux P, LaCombe C. Erythropoietin-induced differentiation of the human erythroleukemia cell line TF-1 correlates with impaired STAT5 activation. EMBO J 15:4174-4181, 1996.
71. Klingmuller U, Bergelson S, Hsiao JG, Lodish HC. Multiple tyrosine residues in the cytosolic domain of the erythropoietin receptor promote activation of STAT5. Proc Natl Acad Sci U S A 93:8324-8328, 1996.
72. Quelle FW, Wang D, Nosaka T, Thierfelder WE, Stravopidis D, Weinstein Y, Ihle JN. Erythropoietin induces the activation of STAT5 through association with specific tyrosines on the receptor that are not required for a mitogenic response. Mol Cell Biol 16: 1622-1631, 1996.
73. Tauchi T, Damen JE, Toyama K, Feng GS, Broxmeyer HE, Krystal G. Tyrosine 426 within the activated erythropoietin receptor binds Syp reduces the erythropoietin required for Syp tyrosine phosphorylation and promotes mitogenesis. Blood 87:4495-4501, 1996.
74. Klingmuller U, Lorenz U, Cantley LC, Neel BC, Lodish HC. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes activation of JAK2 and termination of proliferative signals. Cell 80:729-738, 1995.
75. Shan R, Price JO, Guarde WA, Monia BP, Krantz SB, Zhao ZJ. Distinct roles of JNKs/p38 MAP kinase and ERKs in apoptosis and survival of HCP-57 cells induced by withdrawal or addition of erythropoietin. Blood 94:4067-4076, 1999.
76. Jacobs-Helber SM, Ryan SM, Sawyer JJ. JNK p38 are activated by erythropoietin in (EPO) but are not induced in apoptosis following EPO withdrawal in EPO-dependent HCD 57 cells. Blood 96:933-940, 2000.
77. Krantz SB, Zhao ZJ. Retraction. Blood 97:843, 2001.
78. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Biol 15:551-578, 1999.
79. Zhu H, Bunn HF. How do cells sense oxygen? Science 292:449-451, 2001.
80. 2 sensing. Science 292:464-468, 2001.
81. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. Am Soc Biochem Mol Biol 271:17771-17778, 1996.
82. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional responses to hypoxia. Proc Natl Acad Sci U S A 90:4304-4308, 1993.
83. Semenza GL, Nejfelt Mkl, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci U S A 88:5680-5684, 1991.
84. Beck I, Ramirez S, Weinmann R, Caro J. Enhancer element at the 3′-flanking region controls transcriptional response to hypoxia in the human erythropoietin gene. J Biol Chem 266:15563-15566, 1991.
85. Semenza GL, Wang GI. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required or transcriptional activation. Mol Cell Biol 12:5447-5454, 1992.
86. Beck I, Weinmann R, Caro J. Characterization of hypoxia-responsive enhancer in the human erythropoietin gene shows presence of hypoxia-inducible 120-Kd nuclear DNA-binding protein in erythropoietin-producing and nonproducing cells. Blood 82:704-711, 1993.
87. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem 268:21513-21518, 1993.
88. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270:1230-1237, 1995.
89. Hoffman EC, Reyes H, Chu FF, Sander F, Conley LH, Brooks BA, Hankisnon O. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 252:954-958, 1991.
90. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 242:1412-1415, 1988.
91. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA binding activity: implications for models of hypoxia signal transduction. Blood 82:3610-3615, 1993.
92. Jiang B-H, Zheng JZ, Leung SW, Roe R, Semenza GL. Transactivation and inhibitory domains of hypoxia-inducible factor 1 α: modulation of transcriptional activity by oxygen tension. J Biol Chem 272: 19253-19260, 1997.
93. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci U S A 95:11715-11720, 1998.
94. Fandrey J, Frede S, Ehleben W, Porwol T, Acker H, Jelkmann W. Cobalt chloride and desferrioxamine antagonize the inhibition of erythropoietin production by reactive oxygen species. Kidney Int 51: 492-496, 1997.
95. Maxwell PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher EA, Ratcliffe PJ. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275, 1999.
96. Liu Y, Christou H, Morita T, Laughner E, Semenza GL, Kourembanas S. Carbon monoxide and nitric oxide suppresses the hypoxic induction of vascular endothelial growth factor gene via the 5′ enhances. J Biol Chem 273:15257-15262, 1998.
97. Sogawa K, Numayama-Tsuruta K, Ema M, Abe M, Abe H, Fujii-Kuriyama Y. Inhibition of hypoxia-inducible factor 1 activity by nitric oxide donors in hypoxia. Proc Natl Acad Sci U S A 95:7368-7373, 1998.
98. Gleadle JM, Ebert BL, Ratcliffe PJ. Diphenylene iodonium inhibits the induction of erythropoietin and other mammalian genes by hypoxia: implication for the mechanism of oxygen sensing. Eur J Biochem 234:92-99, 1995.
99. Wang GL, Jiang B-H, Semenza GL. Effect of altered redox states on expression and DNA-binding activity of hypoxia-inducible factor 1. Biochem Biophys Res Commun 212:550-556, 1995.
100. 2-regulated prolyl hydroxylation. Science 292:468-472, 2001.
101. Kivirikko KI, Pihlajaniemi I. Collagen hydroxylases and the protein disulfide isomerase subunit of polyl 4-hydroxylases. Adv Enzymol Relat Areas Mol Biol 72:325-398, 1998
102. 2 and 3 PHDs: How animal cells signal hypoxia to the nucleus. Cell 107:1-3, 2001.
103. Ohh M, Park CW, Ivan M, Hoffman MA, Kim T-Y, Huang LE, Pavletich N, Chou V, Kaelin WG. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von hipple-lindau protein. Nat Cell Biol 2:423-427, 2000.
104. Masson N, William C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J 20:5197-5206, 2001.
105. Epstein CRA, Gleadle JM, McNeill LA, Heurtson KS, O'Rourke J, Mole DR, Mukherji M, Metzern E, Wilson MI, Dhonda A, Tian Y-M, Masson N, Hamilton DL, Jaakkoal P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43-54, 2001.
106. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294:1337-1340, 2001.
107. Kallio PJ, Okamoto K, Obrien S, Carrero P, Makino Y, Tanaka H, Poellinger L. Signal transduction in hypoxic cells: inducible translocation and recruitment of the CBP/P300 coactivator by the hypoxia-inducible factor-1α. EMBO J 17:6573-6586, 1998.
108. Wang GL, Jiang B-H, Semenza GL. Effect of protein kinase and phosphatase inhibitors on expression of hypoxia-inducible factor 1. Biochem Biophys Res Commun 216:669-675, 1995.
109. Kvietikova I, Wenger RH, Marti HH, Gassman M. The transcription factors ATF-1 and CREB-1 bind constitutively to the hypoxia-inducible factor-1 (HIF-1) DNA recognition site. Nucleic Acids Res 23:4542-4550, 1995.
110. Ueno M, Brookins J, Beckman B, Fisher JW. A1 and A2 Adenosine receptor regulation of erythropoietin production. Life Sci 43:229-237, 1988.
111. Mentzer RM Jr., Rubio R, Berne RM. Release of adenosine by hypoxic canine lung tissue and its possible role in pulmonary circulation. Am J Physiol 229:1625-1631, 1975.
112. Minamino T, Kitakazo M, Komamura K, Node H, Takeda H, Inouse M, Hori M, Kamada T. Activation of protein kinase C increases adenosine production in the hypoxic canine coronary artery through the extracellular pathway. Arterioscler Thromb Vasc Biol 15:2298-2304, 1995.
113. 2A receptor gene by hypoxia in PC12 cells. A potential role in cell protection. J Biol Chem 274:20358-20365, 1999.
114. Bakris GR, Sauter ER, Hussey JL, Fisher JW, Gaber AO, Winsett R. Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med 323:86-90, 1990.
115. 2B receptor activation of erythropoietin production. Am J Physiol 281:F826-F832, 2001.
116. Nakashima J, Ohigashi T, Brookins JW, Beckman BS, Agrawal KC, Fisher JW. Effects of 5-N-ethylcarboxamideadenosine on erythropoietin production. Kidney Int 44:734-740, 1993.
117. 2 recepton agonists in response to hypoxia. J Lab Clin Med 126:299-306, 1995.
118. 2B receptors. Pharm Rev 49: 381-402, 1997.
119. Yoshioka K, Clejan S, Brookins J, Fisher JW. Activation of protein kinase C in human hepatocellular carcinoma (HEP3B) cells increases erythropoietin production. Life Sci 63:523-535, 1998.
120. McGary EC, Rondon IJ, Beckman BS. Post-transcriptional regulation of erythropoietin mRNA stability by eyrthropoietin mRNA-binding protein. Proc Natl Acad Sci U S A 88:5149-5153, 1997.
121. Bouritius H, Bojvoth RB, Groot JA. Microelectrode measurements of the effects of basolateral adenosine in polarized human intestinal epithelial cells in culture. Pflugers Arch Eur J Physiol 437:589-595, 1999.
122. Michoud MC, Tao FC, Pradham AA, Martin JG. Mechanisms of the potentiation by adenosine of adenosine triphosphate-induced calcium release in tracheal smooth muscle cells. Am J Resp Cell Mol Biol 21:30-36, 1999.
123. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 316:73-78, 1987.
124. Eschbach J, DeOreo P, Adamson J, et al: rHuEPO clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 30(Suppl 3):S192-S240, 1997.
125. Eschbach JW. Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI. Semin Nephrol 20:320-329, 2000.
126. Kaufman JS, Reda DJ, Fye CL, Goldfarb D, Henderson WG, Kleinman JG, Vaamonde CA. Subcutaneous versus intravenous administration of erythropoietin in hemodialysis patients. N Engl J Med 339: 578-583, 1998.
127. Egrie JC, Eschbach JW, McGuire T, Adamson JW. Pharmacokinetics of recombinant human erythropoietin administered to hemodialysis (HD) patients. Kidney Int 33:262, 1988.
128. Eschbach JW, Haley NR, Adamson JW. The use of recombinant erythropoietin in the treatment of the anemia of chronic renal failure. Ann NY Acad Sci 554:225-230, 1989.
129. Jacobs C, Horl WH, Macdougal TC, Valderrabano F, Parrondo I, Segner A, Abraham TL. European best practice guidelines 5 target haemoglobin. Nephrol Dial Transplant 15(Suppl 4):15-19, 2000.
130. Fisher JW, Bommer J, Eschbach J, Fried W, Lange RD, Massry S, Nathan D, Nolph KD, Teehan BP. Statement on the clinical use of recombinant erythropoietin in anemia of end stage renal disease. Am J Kidney Dis 14:163-169, 1989.
131. Murphy ST, Parfrey PS. Erythropoietin therapy in chronic anemia: the impact of normalization of hematocrit. Curr Opin Nephrol Hypertens 8:573-578, 1999.
132. Kessler M. Value of early management of patients with chronic renal failure. Presse Medicale 26:1340-1342, 1997.
133. Ritz E, Eisenhart A. Early epoetin treatment in patients with renal insufficiency. Nephrol Dialysis Transplant 15(Suppl 3):40-44, 2000.
134. Garcia MM, Beckman BS, Brookins JW, Powell JS, Lanham W, Blaisdell S, Keay L, Li SC, Fisher JW. Development of a new radioimmunoassay for EPO using recombinant erythropoietin. Kidney Int 38:969-975, 1990.
135. McGonigle RJS, Boineau FG, Ohene-Frempong K, Lewy JE, Shadduck RK, Fisher JW. Erythropoietin and inhibitors of in vitro erythropoiesis in the development of anemia in children with renal disease. J Lab Clin Med 105:449-481, 1985.
136. Radtke HW, Rege AB, Lamarche MB, Bartos D, Campbell RA, Fisher JW. Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. J Clin Invest 67:1623-1629, 1980.
137. Macdougall IC. Role of uremic toxins in exacerbating anemia in renal failure. Kidney Int 59(Suppl 78):567-572, 2001.
138. Kushner DS, Beckman BS, Nguyen L, Chen S, Della Santina C, Husserl F, Rice J, Fisher JW. Poyamines in the anemia of end stage renal disease (ESRD). Kidney Int 39:725-732, 1991.
139. Allen DA, Breen C, Yagoog MM, MacDougall IC. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-α and TNF-α. J Invest Med 47:204-211, 1999.
140. Erslev AJ, Besareb A. The rate and control of baseline red cell production in hematologically stable patients with uremia. J Lab Clin Med 126:283-286, 1995.
141. Steiner RW. Characteristics of the hematocrit response to continuous ambulatory dialysis. Arch Intern Med 144:728-732, 1984.
142. McGonigle RJS, Husserl F, Wallin JD, Fisher JW. Hemodialysis and continuous ambulatory peritoneal dialysis effect on erythropoiesis in renal failure. Kidney Int 25:430-436, 1984.
143. Vaziri NA. Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol Hypertens 10:633-637, 2001.
144. Vaziri ND, Zhou XJ, Naqui F, Smith J, Oveisi F, Wang ZQ. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol 271:E113-E122, 1996.
145. Koupke CJ, Kim S, Vaziri ND. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol 4:1874-1878, 1994.
146. Vaziri ND, Zhou M, Smith J, Oveisi F, Baldwin K, Purdy RD. In vivo and in vitro pressor effects of erythropoietin in rats. Am J Physiol 269:F838-F845, 1995.
147. Bode-Boger SM, Boger RH, Kahn M, Rodermacher J, Frohlich JC. Recombinant erythropoietin enhances vasoconstriction tone via endothelin-1 and constrictor prostanoids. Kidney Int 50:1255-1261, 1996.
148. Brochu E, Lacasses S, Lariviere R, Kingma I, Grose JH, Lebel M. Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. J Am Soc Nephrol 10:1440-1446, 1999.
149. Eggena P, Willsey P, Jarngotchian N, Truckenbrod L, Barrett JD, Eggena MP, Clegg K, Nakhoul F, Lee DBN. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol 261:E642-E646, 1991.
150. Bode-Boger SM, Boger RH, Kuhn M. Endothelin release and shift in prostaglandin balance are involved in the modulation of vascular tone by recombinant erythropoietin. J Cardiovasc Pharmacol 20(Suppl 12): 525-528, 1992.
151. Pelletier L, Regnard J, Fellman D, Chrarbord P. An in vitro model for the study of human marrow angiogenesis: role of hematopoietic cytokines. Lab Investig 80:501-511, 2000.
152. Ribatti D, Presta M, Vasca A, Giuliani RR, Dell'Era P, Roncali NB, Dammaco F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93:2627-2636, 1999.
153. Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 47:740-745, 1995.
154. Iimura O, Takahoshi H, Ikeda H, Ito G, Ando Y, Ozawa K, Asano Y, Akimato T, Kiusano E, Inoba TV. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphotidylinositol 3 kinase-dependent pathway. Kidney Int 58:269-282, 2000.
155. Jereen-Sturgic B, Race V, Jeren T, Horavatin-Golder S. Morphologic and functional changes of left ventricle in dialyzed patients after treatment with recombinant human erythropoietin. Angiology 51: 131-139, 2000.
156. Wagner KF, Katschinski DM, Hasegawa J, Schumacher D, Meller B, Gembruck V, Schramm V, Jelkmann W, Gassmann M, Fandrey J. Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin. Blood 97:536-542, 2001.
157. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian J-J, Dupont PM, Michaud P, Papo T, Ugo V, Teyssander I, Varet B, Mayeux P. Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475, 2002.
158. Gogue SR, Beckman BS, Wilson RB, Agrawal KS. Inhibitory effects of zidovudine in erythroid progenitor cells. Reversal with a combination of erythropoietin and interleukin-3. Biochem Pharmacol 50: 413-419, 1995.
159. Henry DH, Beal GN, Benson CA, Cary J, Cone LA. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Ann Int Med 117:730-748, 1992.
160. Fischl M, Galpin JE, Levine JL, Groopman JE, Henry DH, Kennedy P, Miles S, Robbins W, Starrett B, Zalusky R, Abels RI, Tsai HC, Rudnick SA. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med. 322:1488-1493, 1990.
161. Smith DH, Guaneri CM, Whaling SM, Vokes EE. Erythropoietin response in cancer patients receiving cisplatin. Proc Am Assoc Cancer Res 29:52, 1988.
162. Gabrilove JL, Cleeland CS, Livingston RB, Sarakham B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin-α in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three times weekly dosing. J Clin Oncol 19: 2875-2882, 2001.
163. Vercameen E, Rappaport B. Effects of epoetin-α on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874, 2001.
164. De Andrade JR, Jove M. Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin-α in patients undergoing major orthopedic surgery. Am J Orthoped 25:533-546, 1996.
165. Goldberg MA, McCutchen JW. A safety and efficacy comparison study of two dosing regimens of epoetin-α in patients undergoing major orthopedic surgery. Am J Orthoped 25:544-552, 1996.
166. Di Raimondo F, Longo G, Cacciola EJR, Milone G, Palumbo GA, Cacciola RR, Alessi M, Giustolisi R. A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study. Eur J Haematol 56: 7-11, 1996.
167. Thomas MJG, Gillon J, Desmond MJ. Preoperative autologous donation. Transfusion 36:633-639, 1996.
168. Price TR, Goodnough LT, Vogler WR, Sacher RA, Hellman RM, Johnston MFM, Bolgiano DC, Abels RI. The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits: a multicenter, randomized, double-blind, controlled trial. Transfusion 36:29-31, 1996.
169. Harris SA, Payne G Jr., Putman JM. Erythropoietin treatment of erythropoietin-deficient anemia without renal disease during pregnancy. Obstet Gynecol 87:812-814, 1996.
170. Pincus T, Olsen NJ, Russel IJ, Eolfe F, Harms RE. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 89:161-168, 1990.
171. Messer J, Haddad J, Donato L, Astruc D, Matis J. Early treatment of premature infants with recombinant human erythropoietin. Pediatrics 92:519-523, 1993.
172. Bader B, Blondhein O, Jona R, Admoni O, Abend-Winger M, Reich D, Lanis A, Tamier A, Eldar T, Attias D. Decreased ferritin levels despite iron supplementation, and during therapy in the anemia of prematurity. Acta Paediatr 85:496-501, 1996.
173. Steegman JL, Lopez J, Otero MJ, Lamana ML, de la Cámara R, Barberana M, Diaz A, Ferńandeź-Ranada JM. Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: results of a prospective controlled randomized trial. Bone Marrow Transplant 10:541-546, 1992.
174. Pierelli L, Scambia G, Menichella G, d'Onofrio G, Slerno G, Panici PB, Foddai ML, Vittori M, Lai M, Ciarli M, Puglia G, Mancuso S, Bizzi B. The combination of erythropoietin and granulocyte colony-stimulating factor increases the rate of haemopoietic recovery with clinical benefit after peripheral blood progenitor cell transplantation. Br J Haematol 92:287-294, 1996.
175. Goodnough LT, Anderson KC, Kurtz S, Lane TA, Pisciotto PT, Silverstein LE. Indications and guidelines for the use of hematopoietic growth factors. Committee Rep Transfus 33:944-955, 1993.
176. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Int Med 111: 992-1000, 1989.
177. Egrie JC, Grant JR, Gillies DK. The role of the carbohydrate on the biological activity of erythopoietin. Glycoconjugate J 10:263, 1993.
178. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J. Pharmacokinetics of novel erythropoieis protein compared with epoetin-α in dialysis patients. J Am Soc Nephrol 10:2392-2395, 1999.
179. Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dialysis Transplant 16(Suppl 3):14-21, 2001.
180. Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, Gray SJ. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 60:741-747, 2001.
181. Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erthropoietin). Clin Pharmacokinetics 20:99-113, 1991.
182. Macdougall IC, Gary SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin-α in dialysis patients. J Am Soc Nephrol 10: 2392-2395, 1999.
183. Macdougall IC, on behalf of the UK NESP Study Guide. Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anemia. J Am Soc Nephrol 9:258A-259A, 1998.
184. Korbert SM. Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis. Kidney Int 43:S111-S119, 1993.
185. Vanrenterghem Y, Barany P, Mann J. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin in ESRD patients when administered once-weekly or once every other week. J Am Soc Nephrol 10:270A, 1999.
186. The Medical Letter on Drugs and Therapeutics. Darbepoetin (ARANESP) = a long-acting erythropoietin. Rochelle, NY: The Medical Letter, Inc. Vol. 43(1120) pp 109-110, 2001.
187. Pace N. The increase in hypoxia tolerance of normal men accompanying the polycythemia induced by transfusion of erythocytes. Am J Physiol 148:152-163, 1947.
188. Ekblom B, Goldbard AN, Gullbring B. Response to exercise after blood loss and reinfusion. J Appl Physiol 33:175-180, 1972.
189. Ekblom B, Berglund B. Effect of erythropoietin administration on maximal aerobic power. Scand J Med Sci Sports 1:88-93, 1991.
190. Jelkmann W. Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr Pharmaceut Biotechnol 1:11-31, 2000.
191. Jelkmann W. Beneficial and adverse effects of erythropoietin therapy. In: Peters C, Schulz T, Michnam H, Druck, Eds. Biomedical Side Effects of Doping. Germany: Hansen, Bergisch Gladbach. pp59-73,2001.
192. Shaskey DJ, Green GA. Sports haematology. Sports Med 29:27-38, 2000.
193. Breymann C. Erythropoietin test methods. Best Practice Res Clin Endocrinol Metab 14:135-145, 2000.
194. Sieff CA, Nathan DG. Haemopoietic stem cells. In: Weatherall DJ, Ledingham JGG, Warren DA, Eds. Oxford Textbook of Medicine (3rd ed). Oxford, UK: Oxford University Press, pp3381-3390, 1996.
195. Marti HH, Bernaudin M. Function of erythropoietin in the brain. In: Wolfgang J, Ed. Erythropoietin: Molecular Biology and Clinical Use. Johnson City, Tennessee: F. P. Graham Publishing Co., pp 195-215, 2002.
196. Juul S. Erythropoietin in the central nervous system and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr 438(Suppl):36-42, 2002.